Safety and efficacy of combo therapy of interferon-a2 and ruxolitinib in polycythemia vera and myelofibrosis

by Stine Ulrik Mikkelsen, Lasse Kjær, Mads Emil Bjørn, Trine Alma Knudsen, Anders Lindholm Sørensen, Christen Bertel Lykkegaard Andersen, Ole Weis Bjerrum, Nana Brochmann, Daniel El Fassi, Torben A. Kruse, Thomas Stauffer Larsen, Hans Torben Mourits‐Andersen, Claus Henrik Nielsen, Niels Pallisgaard, Mads Thomassen, Vibe Skov, Hans Carl Hasselbalch Abstract Interferon‐α2 reduces elevated blood cell counts […]

Heidi’s MPN Story – An Increasing Trend in Patient Advocacy

by Heidi Cascarano “Watch and Wait…” What other cancer, in the 21st century, is so misunderstood that your local doctor will struggle to diagnose you, possibly tell you he has a few other patients with it, then advise you to do nothing but get a therapeutic phlebotomy and take a baby aspirin?  You get online […]

An Opportunity to improve measurement of health related quality of life symptoms using MPN Patient reported outcomes

A Patient’s Perspective – Methods to Improve MPN Research by Collecting data and Blood test results from Patients by David Wallace As a PV patient, my treatment has run a wide spectrum during the last 6 years.  Starting with phlebotomy only, Hydroxyurea (short time frame), Pegasys (nearing 2 years) and now the “cutting edge combo” […]

PV For Newbies – A Patient’s Perspective

by Dave Stewart YOU’VE JUST BEEN DIAGNOSED WITH PV… …and now, most likely, you’re looking online for info…anything…to tell you what to expect, what’s next, how long you’re going to live… First things first – Don’t panic.  Easier said than done, but learning how to control your stress and keep it at a healthy level […]

MPD-RC 111 Clinical Trial for High Risk Polycythemia Vera or Essential Thrombocythemia

Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Ruben Mesa, M.D., hematologist at Mayo Clinic in Arizona, discusses the Myeloproliferative Disorders Research Consortium (MPD-RC 111), a clinical trial investigating single arm salvage therapy with pegylated interferon alfa-2a for patients with high risk polycythemia vera or high risk essential […]

MPD-RC 112 Clinical Trial for High Risk PV and ET Patients

Randomized Clinical Trial of Pegylated Interferon alfa-2a versus Hydroxyurea Ruben Mesa, M.D., hematologist at Mayo Clinic in Arizona, discusses MPD-RC 112, a randomized trial of pegylated interferon alfa-2a versus hydroxyurea therapy in the treatment of high risk polycythemia vera (PV) and high risk essential thrombocythemia (ET). Key Points:  Why are we doing the Study? Top […]

Emerging Drugs for Polycythemia Vera

Polycythem Vera – Expert Opinion on Emerging Drugs Raoul Tibes, Ruben A Mesa Mayo College of Medicine, Mayo Clinic, Mayo Clinic Cancer Center, Division of Hematology & Medical Oncology , 13400 E. Shea Boulevard, Scottsdale, AZ 85259 , USA +1 480 301 6740 ; +1 480 301 4675 ; . Expert Opinion on Emerging Drugs (Impact Factor: […]

 
error: Content is protected !